Skip to main
TRML
TRML logo

TRML Stock Forecast & Price Target

TRML Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tourmaline Bio Inc has demonstrated a robust stock performance, with shares increasing over 30% since their launch, significantly outperforming the biotech index. The company's estimated market value has risen to $1.29 billion, indicating a strong financial standing, while the potential revenue from international markets could lead to an increased valuation of approximately $53 per share, driven by promising clinical data. Furthermore, the company's initial product candidate, TOUR006, shows potential for a competitive advantage in treating life-altering immune diseases, particularly by addressing cardiovascular risk profiles, which adds to the overall positive outlook for the stock.

Bears say

Tourmaline Bio Inc has experienced significant stock underperformance, with shares declining by 35% year-to-date in 2025 compared to a modest 1% return for the NASDAQ Biotechnology Index. The company's financial outlook remains precarious, with a net loss of $73.2 million reported for 2024 and potential valuations dropping to as low as $10 per share in a worst-case scenario involving the termination of its product candidate pacibekitug. Additionally, concerns regarding the efficacy of pacibekitug in the ASCVD space, particularly in light of competitor data, further exacerbate the financial risks faced by the company.

TRML has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tourmaline Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tourmaline Bio Inc (TRML) Forecast

Analysts have given TRML a Buy based on their latest research and market trends.

According to 10 analysts, TRML has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tourmaline Bio Inc (TRML)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.